Beryl Drugs Ltd files SEBI SAST disclosure for Sudhir Sethi

What Beryl Drugs Ltd announced

Beryl Drugs Ltd (BSE: 524606) filed a disclosure with the Bombay Stock Exchange on 29 June 2026 under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing pertains to Sudhir Sethi, who has made a substantial acquisition of the company’s shares. The announcement itself does not provide the size of the stake or the exact number of shares acquired.

Regulation 29(1) disclosure – what it entails

Regulation 29(1) requires any person or entity that acquires shares crossing the 1 % threshold of a listed company’s paid‑up capital to inform the stock exchange within two trading days. The purpose is to ensure market transparency and allow other shareholders to assess changes in control. In this case, Sudhir Sethi’s acquisition has crossed that threshold, prompting the filing.

Key facts at a glance

Why this matters for investors

The disclosure signals that a significant shareholder has entered the capital structure of Beryl Drugs. While the exact size of the holding is not disclosed, the fact that the acquisition crossed the 1 % trigger point may affect voting dynamics and could lead to further share‑holding disclosures if the stake increases. Investors should monitor subsequent filings for details on the percentage held, any lock‑in periods, and whether the acquirer intends to seek board representation or influence corporate strategy.

Conclusion

Beryl Drugs Ltd has complied with SEBI’s SAST regulations by reporting Sudhir Sethi’s substantial share purchase on 29 June 2026. The filing confirms a material change in shareholding but does not disclose the precise stake. Future disclosures, if any, will provide clearer insight into the extent of the acquisition and its potential impact on corporate governance.